Treatment of chronic hepatitis B: Recommendations from an Italian workshop

被引：43

作者：

Carosi, G. ^{[1
]}

Rizzetto, M. ^{[2
]}

机构：

[1] Univ Brescia, Dept Infect & Trop Dis, Brescia, Italy

[2] Univ Turin, Dept Gastroenterol, Turin, Italy

来源：

DIGESTIVE AND LIVER DISEASE | 2008年 / 40卷 / 08期

关键词：

antiviral therapy; cirrhosis; HBV; HCV; HDV; HIV; immune suppressed;

D O I：

10.1016/j.dld.2008.03.011

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The changing scenario of hepatitis B virus therapy has encouraged the organisation of a workshop, endorsed by three Italian scientific societies, aimed at defining the current recommendations for hepatitis B virus treatment. Liver histology and stage of disease remain fundamental for treatment decisions; interferon and nucleoside/nucleotide analogues-based therapy represent different strategies for different phases of the hepatitis B virus disease. The recommendations defined: new and lower cut-off of hepatitis B virus-DNA for eligibility to therapy according to disease stage, how to optimise the use of nucleoside/nucleotide analogues and to individualise the monitoring of response and what to do with treatment failures. Specific recommendations have also been given for cirrhosis patients, those immune suppressed and co-infected with HIV and other hepatitis viruses. (C) 2008 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

引用

收藏

页码：603 / 617

页数：15

相关论文

共 206 条

[1] Can serum HBV-DNA be used as a primary end point to assess efficacy of new treatments for chronic hepatitis B? [J].

Alberti, A .

HEPATOLOGY, 2003, 38 (01) :18-20

[2] Recent progress and new trends in the treatment of hepatitis B [J].

Alberti, A ;

Brunetto, MR ;

Colombo, M ;

Craxì, A .

JOURNAL OF MEDICAL VIROLOGY, 2002, 67 (03) :458-462

[3] Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients [J].

Alberti, A ;

Clumeck, N ;

Collins, S ;

Gerlich, W ;

Lundgren, J ;

Palù, G ;

Reiss, P ;

Thiebaut, R ;

Weiland, O ;

Yazdanpanah, Y ;

Zeuzem, S .

JOURNAL OF HEPATOLOGY, 2005, 42 (05) :615-624

[4] Identification and characterization of mutations in hepatitis B virus resistant to lamivudine [J].

Allen, MI ;

Deslauriers, M ;

Andrews, CW ;

Tipples, GA ;

Walters, KA ;

Tyrrell, DLJ ;

Brown, N ;

Condreay, LD .

HEPATOLOGY, 1998, 27 (06) :1670-1677

[5] Lamivudine-associated remission of chronic hepatitis delta [J].

Andreone, P ;

Spertini, F ;

Negro, F .

ANNALS OF INTERNAL MEDICINE, 2000, 132 (07) :598-598

[6] Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase [J].

Angus, P ;

Vaughan, R ;

Xiong, S ;

Yang, HL ;

Delaney, W ;

Gibbs, C ;

Brosgart, C ;

Colledge, D ;

Edwards, R ;

Ayres, A ;

Bartholomeusz, A ;

Locarnini, S .

GASTROENTEROLOGY, 2003, 125 (02) :292-297

[7] Natural history of hepatitis B and C in renal allograft recipients [J].

Aroldi, A ;

Lampertico, P ;

Montagnino, G ;

Passerini, P ;

Villa, M ;

Campise, MR ;

Lunghi, G ;

Tarantino, A ;

Cesana, BM ;

Messa, P ;

Ponticelli, C .

TRANSPLANTATION, 2005, 79 (09) :1132-1136

[8] Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus [J].

Bani-Sadr, F ;

Palmer, P ;

Scieux, C ;

Molina, JM .

CLINICAL INFECTIOUS DISEASES, 2004, 39 (07) :1062-1064

[9] Prompt relapse of viremia after lamivudine discontinuation in e-minus chronic hepatitis B patients completely responders during 5 years of therapy [J].

Barbon, V ;

Gaia, S ;

Marzano, A ;

Lagget, M ;

Rizzetto, M .

JOURNAL OF HEPATOLOGY, 2004, 41 (03) :500-501

[10] Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation [J].

Bartholomew, MM ;

Jansen, RW ;

Jeffers, LJ ;

Reddy, KR ;

Johnson, LC ;

Bunzendahl, H ;

Condreay, LD ;

Tzakis, AG ;

Schiff, ER ;

Brown, NA .

LANCET, 1997, 349 (9044) :20-22

← 1 2 3 4 5 6 7 8 9 10 →